Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents

Signal Transduct Target Ther. 2021 Feb 15;6(1):62. doi: 10.1038/s41392-020-00430-1.

Abstract

Cancer stem cells (CSCs) show a self-renewal capacity and differentiation potential that contribute to tumor progression and therapy resistance. However, the underlying processes are still unclear. Elucidation of the key hallmarks and resistance mechanisms of CSCs may help improve patient outcomes and reduce relapse by altering therapeutic regimens. Here, we reviewed the identification of CSCs, the intrinsic and extrinsic mechanisms of therapy resistance in CSCs, the signaling pathways of CSCs that mediate treatment failure, and potential CSC-targeting agents in various tumors from the clinical perspective. Targeting the mechanisms and pathways described here might contribute to further drug discovery and therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Cell Differentiation / genetics
  • Drug Resistance, Neoplasm / genetics*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplastic Stem Cells / drug effects*
  • Neoplastic Stem Cells / pathology
  • Signal Transduction / drug effects

Substances

  • Antineoplastic Agents